Key points are not available for this paper at this time.
The combination of regorafenib 80 mg plus nivolumab had a manageable safety profile and encouraging antitumor activity in patients with gastric and colorectal cancer, which warrants additional investigations in larger cohorts.
Fukuoka et al. (Tue,) studied this question.